The rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Those shots could provide a longer-lasting and more convenient option than daily insulin and other common treatments for managing diabetes.every day. Meanwhile, roughly a third of people with Type 2 diabetes need insulin injections to keep their blood sugar within a healthy range, according to some. But some resist or delay treatment due to inconvenience and pain, among other reasons, which could worsen their long-term health.dominance in the insulin market.
At the end of 52 weeks, patients on efsitora saw a reduction of 1.34% in their A1C – a marker of blood sugar levels over three months – compared with a 1.26% reduction for insulin degludec. Eli Lilly added that its injection was as effective in lowering A1C levels as the daily insulin, regardless of whether patients were taking a GLP-1 in the study.
Swathi Bhat, head of product at Uber Health, said the company knows it's not just doctors and nurses that provide care to others. In fact, she noted that nearly 25% of Americans identify as caregivers, according to the Centers for Disease Control and Prevention.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk, Eli Lilly drop on Amgen competition concernsNovo Nordisk, Eli Lilly drop on Amgen competition concerns
Read more »
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slideAmgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.
Read more »
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supplyEli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch’s heart monitoring tech was approved for use in clinical…
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supplyEli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch’s heart monitoring tech was approved for use in clinical…
Read more »
Why Lilly And Novo Nordisk Will Keep Dominating The Market For Blockbuster GLP-1 DrugsAlex Knapp is a senior editor at Forbes covering healthcare, science, and cutting edge technology who joined Forbes in 2011. He's written dozens of profiles of entrepreneurs across a variety of fields and done deep dives into technological trends from superconductors to space travel to pharmaceuticals.
Read more »